磺胺托嘧啶 | 3772-76-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 磺胺托嘧啶
• 英文名称: sulfametomidine
• 英文别名: sulfamethoxazole；sulfamidine；ZINC00002098；4-amino-N-(6-methoxy-2-methyl-pyrimidin-4-yl)-benzenesulfonamide；sulfanilic acid-(6-methoxy-2-methyl-pyrimidin-4-ylamide)；Sulfanilsaeure-(6-methoxy-2-methyl-pyrimidin-4-ylamid)；4-amino-N-(6-methoxy-2-methylpyrimidin-4-yl)benzenesulfonamide
• CAS: 3772-76-7
• 化学式: C₁₂H₁₄N₄O₃S
• 分子量: 294.334
• InChiKey: QKLSCPPJEVXONT-UHFFFAOYSA-N

物化性质

• 熔点：
  146°
• 沸点：
  501.6±60.0 °C(Predicted)
• 密度：
  1.3518 (rough estimate)
• 溶解度：
  0.00 M

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2935009090

制备方法与用途

磺胺甲脒是一种抗菌剂。

反应信息

• 作为产物：
  描述：

  6-甲氧基-2-甲基-4-嘧啶胺 在 吡啶 、 sodium hydroxide 、 苯 作用下， 生成 磺胺托嘧啶
  参考文献：
  名称：

  DE926131

  摘要：

  公开号：

文献信息

• COMPOUNDS AND COMPOSITIONS FOR DRUG RELEASE
  申请人：INTERFACE BIOLOGICS, INC.

  公开号：US20160038651A1

  公开（公告）日：2016-02-11

  The invention relates to compounds that include biologically active agents (e.g., compounds according to any of formulas (I) and (I-A) that can be used for effective drug release, e.g., as coatings for medical devices. Use of these compounds in the coating of surfaces can allow for long-term drug release as well as imparting uniform coatings with little phase separation compared to, e.g., the parent biologically active agent.

  这项发明涉及包括生物活性剂（例如，根据任何公式（I）和（I-A）的化合物）的化合物，可用作有效的药物释放，例如，作为医疗器械的涂层。在表面涂层中使用这些化合物可以实现长期药物释放，并且与原生生物活性剂相比，可以实现均匀涂层且几乎没有相分离。
• Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2601941A1

  公开（公告）日：2013-06-12

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及beta-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，及其医药用途，包括用于治疗或预防细菌以及原生动物感染，特别是治疗或预防革兰氏阳性细菌和/或革兰氏阴性细菌引起的感染和传染病以及与之相关的感染和传染病。该发明还涉及这些化合物用于预防或消除生物膜。
• [EN] BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS<br/>[FR] COMPOSÉS À BASE DE BÊTA-O/S/N ACIDES GRAS EN TANT QU'AGENTS ANTIBACTÉRIENS ET ANTI-PROTOZOAIRES
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2013083724A1

  公开（公告）日：2013-06-13

  The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

  本发明涉及β-O/S/N脂肪酸及其衍生物，特别是如本文所述和定义的公式(I)化合物，以及它们的医药用途，包括用于治疗或预防细菌以及原生动物感染，尤其是治疗或预防革兰氏阳性菌和/或革兰氏阴性菌感染以及由革兰氏阳性菌和/或革兰氏阴性菌引起的传染病。本发明进一步涉及使用这些化合物来预防或消除生物膜。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
  申请人：——

  公开号：US20020182185A1

  公开（公告）日：2002-12-05

  Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

  描述了减少或预防个体眼部移植排斥的方法，包括：a) 执行眼部移植手术；和b) 植入眼部一个生物可降解药物输送系统，包括免疫抑制剂和生物可降解聚合物。